Abstract: Urothelial carcinoma is well known for its divergent differentiation. Several ''variant'' morphologies have been described in the literature in recent years and have additionally been recognized in the recent World Health Organization classification of urothelial neoplasms. The importance of recognizing these variant histologies lies in the potential diagnostic, prognostic, or therapeutic implications that accompany these diagnoses. The range of variant morphology seen in the urinary bladder may also be seen in urothelial tumors of the renal pelvis. Herein we review select variants of urothelial carcinoma focusing on the relatively recently recognized variants, outlining the diagnostic features, common differential diagnostic dilemmas, and clinical relevance. This review also includes a discussion on variants on which there is recent information available.
U
rothelial carcinoma is well known for its divergent differentiation, which occurs most commonly as foci of glandular or squamous differentiation. In recent years, with increasing experience with bladder cancer, the morphologic spectrum has been expanded to include several new variants. The range of variant morphology seen in the urinary bladder may also be seen in tumors of the renal pelvis and has been incorporated in the recent World Health Organization (WHO) classification (Table  1) . 1, 2 The importance of recognition of these variants lies in the diagnostic, prognostic, and therapeutic considerations that may occur as a result of a particular diagnosis being made. The presence of ''variant'' histology should be documented in the pathology report as tumor at metastatic sites will often retain the primary variant morphology and this information will help the pathologist make the correct diagnosis and association with urothelial carcinoma. Herein we review the clinical and pathologic features of the recently described morphologic variants of urothelial carcinoma; in some established variants we provide an update of new information.
UROTHELIAL CARCINOMA WITH DECEPTIVELY BLAND FEATURES Nested Variant
Stern 3 reported the first case of a bladder tumor consisting of proliferative benign von Brunn's nests in 1979. Talbert and Young 4 subsequently characterized this neoplasm as a carcinoma with deceptively bland features, which mimicked the morphologic appearance of common benign conditions, such as von Brunn's nests, nephrogenic adenoma, or cystitis cystica. The term ''nested variant'' was initially coined by Murphy and Deana 5 in 1992. The authors recognized an unusual urothelial neoplasm, which initially manifested as small nests and abortive tubules infiltrating the lamina propria. 5 Since then there have been several cases reported in the literature, most in the form of cases reports, with the largest series describing 16 cases. 6 Although the majority of cases occur in the urinary bladder, there have been recent reports of this entity in the upper urinary tract. 7, 8 The approximate incidence of this variant is reported to be 0.3% of all urothelial carcinomas although this may be a bias toward more unique cases being preferentially reported in the literature. 7 Histologically, this tumor is characterized by nests of tumor cells that have a relatively bland cytologic appearance but have a subtle but often appreciable degree of cytologic atypia when compared with benign urothelium ( Fig. 1, plate I) . 9 The tumor may show greater cytologic atypia toward the deeper portions of the tumor, a finding that may not be fully appreciated in smaller tissues (Fig. 1D, plate I) . 10 Keys to the recognition of this deceptive pattern of carcinoma include tightly packed, often confluent, and haphazard arrangement of nests. In some tumors, there may be an admixed, sometimes prominent, component of tubular, or small glandular histology (Fig. 1A, plate I) .
The main differential diagnostic consideration is that of proliferative von Brunn's nests (Fig. 2) . The tumor nests of nested urothelial carcinoma are more closely packed and have a haphazard arrangement with an infiltrating border, in contrast to von Brunn's nests which are usually of relative uniform size and shape, organized, and have a sharp, linear border with an appreciable base. In the upper urinary tract, the von Brunn's nests may be more prominent but the nests are smaller and maintain a lobular or linear configuration and a well-demarcated boundary with the underlying subepithelial connective tissue. Some cases 7, 9 may have a synchronous conventional urothelial carcinoma component but it has been our experience that most tumors may completely lack any association with typical urothelial carcinoma, compounding the diagnostic challenge. Cytokeratin (CK) 7 and 20 immunostains are positive in keeping with the immunoprofile of urothelial carinoma. 9 Despite its innocuous appearance, this variant has been reported to have an aggressive behavior, with outcome similar to that of conventional urothelial carcinoma of similar stage. The tumors may be muscleinvasive at presentation (Fig. 1B, plate I) . 6, 7, 11, 12 Lin et al 11 demonstrated that nested urothelial carcinomas may demonstrate certain poor prognostic features that have been previously reported with aggressive conventional urothelial carcinoma, such as loss of p27 expression. However, other biologic markers that are associated with a poor prognosis in conventional urothelial carcinomas, such as p53, bcl2, and epidermal growth factor receptor seem to be absent in the nested variant of urothelial carcinoma. In addition, these tumors may be associated with a high proliferation index, a finding that suggests that a MIB-1 immunostaining may have diagnostic utility in separating nested variant of urothelial carcinoma from other benign lesions; the utility in any given case remains unproven. 7, 11, 12 Urothelial Carcinoma With Small Tubules
There has been recent emphasis on urothelial carcinomas with prominent small tubular morphology, a feature that may lead to their being misdiagnosed as tubules of nephrogenic adenoma. 13 Some of these tubules develop in small nests of urothelial carcinoma lined by urothelium, in contrast to the typically cuboidal, columnar, hob-nailed, or occasionally flattened cells that line the tubules of nephrogenic adenoma (Fig. 3) .
14 This histology may be pure or admixed with nested pattern (Fig. 1A, plate I) ; nephrogenic adenoma may also have a nested appearance. Tumors may be widely invasive despite a deceptively bland histology. The biologic significance of this pattern is uncertain but appears to be related to the stage of the tumor.
Huang et al 15 have recently described a unique case composed of small tubules that had morphologic features similar to prostatic adenocarcinoma. The tumor showed small compact acini and tubules lined by cuboidal cells with scant eosinophilic cytoplasm and prominent nucleoli, closely resembling a Gleason score 6 prostatic adenocarcinoma. Areas with more typical urothelial carcinoma histology may be present and help in separating this tumor from metastatic prostatic adenocarcinoma. A cautionary note is in order as we have seen rare cases of both urothelial carcinoma and prostatic carcinoma in the same specimen. When in doubt, immunohistochemical stains for prostate-specific markers may be invaluable in differentiating the 2 entities.
MICROPAPILLARY VARIANT
Micropapillary urothelial carcinoma was first described in 1994 as an aggressive variant of urothelial carcinoma with distinctive histologic features reminiscent of the papillary configuration seen in ovarian papillary serous tumors. 16 This rare histologic variant comprises approximately 0.6% to 1% of urothelial carcinomas and shows a strong male predominance (male to female ratio 5:1 to 10:1). 17 The micropapillary component of these tumors may be encountered in the surface noninvasive component, the invasive component of the tumor or in metastatic sites. In the primary tumor, the surface component often presents with delicate filliform projections with secondary or tertiary hierarchical branching often without a (Fig. 4B ). This pattern is especially characteristic of this tumor and is often retained at metastatic sites (Fig. 4D) . Awareness that lacunae of micropapillary urothelial carcinoma may mimic vascular-lymphatic invasion is important to prevent overdiagnosis of the presence of this feature, which is considered to be an adverse prognosticator in urothelial carcinoma. Immunohistochemistry with antibodies against CD31 may help to distinguish true vascularlymphatic invasion from mere retraction artifact surrounding the invasive tumor nests although vascularlymphatic invasion is frequently present in most cases and usually recognized by routine light microscopy. 18, 19 The histology may be pure, predominant, or focal and admixed with usual urothelial carcinoma.
The immunohistochemical profile (CK7+ and CK20+) is similar to that of conventional urothelial carcinoma supporting that it is a variant of urothelial carcinoma. As the histology may be composed exclusively of a micropapillary component, this immunostaining pattern may be particularly helpful in conjunction with other differentiation-associated markers (estrogen receptor, progesterone receptor, TTF-1, and uroplakin) in the diagnosis of micropapillary urothelial carcinomas at metastatic sites.
The differential diagnosis includes other tumors with micropapillary histology including lung, breast, pancreas, salivary glands, etc. 20 In addition to the conventional markers of urothelial differentiation, membranous staining of CA125 has been reported at a higher frequency in the micropapillary component. 19 Cytoplasmic epithelial membrane antigen (EMA) and carcinoembryonic antigen staining in urothelial carcinoma has been shown to be influenced by grade, with more frequent staining in higher grade urothelial carcinomas. Micropapillary urothelial carcinoma shows expression of these 2 markers at a higher frequency, which is in keeping with the aggressive behavior of the particular variant. 18 Maranchie et al 19 demonstrated that despite their aggressive clinical behavior, these tumors do not show altered expression of p53, a feature associated with invasive urothelial carcinomas. The ability of these tumors to disrupt the stromal matrix and extend along tissue planes prompted the same authors to study the role of cell adhesion molecules, specifically the cadherin/catenin complex in the histogenesis of these tumors. They noted that this variant does not demonstrate alterations in the cadherin/catenin complex and inferred that the absence of common molecular changes that are typically noted in urothelial carcinomas may be a consequence of these tumors following a unique pathway to malignant change. 19 The majority of these tumors (>90%) present with at least stage pT1 disease at the time of diagnosis and have a 5-year and 10-year survival rate of 54% and 27%, respectively. 17 Additionally, tumors with >50% micropapillary component in the tumor have a higher relative mortality risk when compared with patients who have a smaller micropapillary component in the tumor. 17, 22 Early cystectomy, is advocated by some institutions for pT1 disease, as intravesical Bacillus Calmette-Guerin (BCG) therapy is often ineffective in these patients. 21 Patients are at a high risk for treatment failure and are managed much in the same manner as patients with known lymphovascular invasion. 22 The poor outcome in these patients underscores the need for an early and accurate diagnosis in these patients.
UROTHELIAL CARCINOMA WITH UNUSUAL CYTOPLASMIC FEATURES Urothelial Carcinoma With Clear Cell Features
The prominence of a clear cell histology in urothelial carcinoma was first highlighted by Kotliar et al in 1995. 23 Since then, approximately 10 cases have been described although we suspect that this feature is not as uncommon as suggested by the literature. The tumor cells are characterized by optically clear cytoplasm which may be focal or extensive and involve both the in situ and invasive components (Figs. 5A, B) . 24 The presence of urothelial carcinoma with more typical morphology and/or identification of surface urothelial lesions help in the appropriate characterization as a primary urothelial carcinoma.
The main differential diagnoses include a clear cell adenocarcinoma of the bladder, metastatic renal cell carcinoma (RCC), and prostatic adenocarcinoma involving the bladder. Clear cell adenocarcinomas of the bladder occur more frequently in women and typically show a wide range of morphologic patterns within the same tumor including a solid, papillary, or tubulocystic architectural arrangement. The papillae are lined by a single epithelial layer with a hyalinized core. The cytoplasm may be eosinophilic or clear and the cells may have a hob-nailed appearance. 25 It has been our observation that when these tumors involve the urinary bladder, the tumor cells usually do not have conspicuous areas with clear cytoplasm. Metastatic RCC, usually clear cell type can be excluded on clinical grounds (presence of a renal mass) although a bladder manifestation may be the first presentation or, metastatic involvement of the bladder may occur several years after nephrectomy. The presence of a renal primary should be suspected when one observes nests of tumor cells in an alveolar pattern, surrounded by a rich and delicate vascular network in the absence of a surface urothelial lesion.
Immunohistochemically, urothelial carcinoma with clear cell features stains strongly for CK7, which is in contrast to clear cell adenocarcinoma in which the staining pattern is rarely diffuse. 25 In our experience, CA-125 has little value in this setting. Coexpression of cytokeratin and vimentin and staining for RCC antigen and PAX-2 with negative reaction for CK 7 and 20 argue for the diagnosis of RCC.
Not much is known about the outcome of these tumors; however, a recent paper suggests that certain urothelial carcinomas with nonconventional differentiation, including tumors with clear cell morphology may have a higher propensity for lymph node metastasis. 26 FIGURE 4. Micropapillary urothelial carcinoma. A, Micropapillary urothelial carcinoma often shows a filliform appearance on the surface with or without a fibrovascular core. B, Note the prominent retraction artifact that surrounds the nests of invasive tumor cells. C, Muscle-invasive micropapillary urothelial carcinoma. The tumor nests splay the fibers of the muscularis propria. The tumor nests show a retraction space around the invasive tumor nests (inset). D, Example of a metastatic micropapillary urothelial carcinoma to a lymph node. The tumor often retains its micropapillary morphology at metastatic sites.
Plasmacytoid Variant
The first case of plasmacytoid urothelial carcinoma was first described by Sahin et al in 1991. 27 The authors described a tumor composed of plasmacytoid cells, in a patient presenting with multiple lytic lesions of the bone that led to a misdiagnosis of plasmacytoma in an initial biopsy. Since their original report, there have been approximately 30 cases reported in the literature most in the form of case reports or small case series. 28, 29 We view these carcinomas to belong to the poorly differentiated to undifferentiated end of the spectrum of urothelial carcinoma. Tumors are composed of sheets or single cells resembling plasma cells infiltrating the wall of the bladder (Fig. 6A and B, plate II). There is an eccentrically placed nucleus, which may be small and when this pattern is predominant the overall impression may be that of non-neoplastic inflammatory infiltrate. Like plasma cells, the cytoplasm is eosinophilic. Frequently, the stroma has a prominent myxoid quality. Plasmacytoid urothelial carcinoma may be pure or admixed with different patterns of urothelial carcinoma including sarcomatoid urothelial carcinoma. A spectrum of cytoplasmic differentiation, including intracytoplasmic lumina occasionally containing mucin may be present. We make the distinction from a signet ring cell carcinoma component based on whether the signet ring cell morphology is focal or more diffuse, and whether the nuclei are indented and pushed to the periphery because of the intracytoplasmic contents, as is often noted in true signet ring cell carcinoma. There have been 2 unique reports of tumors demonstrating plasmacytoid morphology in combination with a lipoid cell variant of urothelial carcinoma; one as an isolated case report and the other case being one of 5 cases of a larger series. 30, 31 Baldwin et al 28 described a ''discohesive variant'' with marked overlap with metastatic lobular carcinoma of the breast, which we believe is within the spectrum of this variant. In their series of 10 patients, they report cytologically innocuous tumor cells arranged in a single file pattern that were often deeply invasive into the bladder wall. The majority of tumors in their series stained positively for CK20 and were negative for estrogen receptor, both findings that are more in keeping with a carcinoma of urothelial origin than a metastatic breast carcinoma. Clinical history of breast cancer is important as metastatic lobular carcinomas usually show widespread metastasis and rarely present primarily with urinary tract symptoms. 32 Examination of the overlying urothelium may reveal a conventional high-grade urothelial carcinoma, however, this finding may not be appreciable in limited and small biopsies. 33 It has been our experience that in small biopsy specimens the distinction between plasmacytoid variant of urothelial carcinoma, plasmacytoma, lymphoma, or even an inflammatory process may be particularly problematic though the distinction from a hematopoietic process may be resolved by immunohistochemistry. A compounding factor in the immunohistochemical staining pattern of these tumors is that the tumor cells often express CD138, a marker of plasma cell differentiation (Figs. 6C, D, plate II) . 29 It is therefore our routine practice to order a cytokeratin stain whenever a CD138 stain is ordered in the context of the differential diagnosis of a carcinoma. There has been a single case report of a plasmacytoid urothelial carcinoma coexpressing CA19-9 and beta human chorionic gonadotropin (bhCG) in the absence of a trophoblastic component. 34 The prognosis of tumors with this morphology is uniformly poor with most patients having advanced stage of disease at presentation and metastatic disease progression. 26, 29, 30 Urothelial Carcinoma With Rhabdoid Features This is a rare recently described variant of urothelial carcinoma, of which approximately 10 cases have been reported in the literature thus far, most in the form of case 35 Carcinomas with rhabdoid features occur in sheets in which the cells are large, round, or oval, with abundant brightly eosinophilic cytoplasm, containing an eosinophilic body composed of intermediate filaments (Fig. 7A,  plate I) . 36, 37 The exact amount of rhabdoid morphology in a carcinoma required to make this specific diagnosis is not defined although in the series described by Parwani et al 40% to 80% of the tumor cells in their cases had a rhabdoid morphology. Most reported cases have demonstrated the concurrent presence of conventional urothelial carcinoma at least focally, and there have been at least 2 cases in association with a sarcomatoid urothelial carcinoma. 38, 39 Immunohistochemical stains against EMA and cytokeratin are usually positive in the rhabdoid cells (Fig. 7B, plate I) . 35 The main distinction is from a true malignant extrarenal rhabdoid tumor that may occur in the bladder. The discovery that primary rhabdoid tumors demonstrate deletions of chromosome 22q11.2 led to the identification of hSNF5/INI1/SMARCB1/BAF47 as a candidate tumor suppressor gene involved in the pathogenesis of renal and extrarenal rhabdoid tumors. 40 Given that true malignant rhabdoid tumors have a characteristic mutation or deletion of the INI1 gene at chromosome 22q11, we suggest ancillary confirmation before the rare diagnosis of malignant rhabdoid tumor in the bladder is rendered in the bladder. Immunohistochemical loss of nuclear INI1 expression has also been reported as an adjunctive test to confirm the diagnosis of malignant extrarenal rhabdoid tumors. 41 There are 2 case reports of ''true'' malignant rhabdoid tumors of the bladder in young patients but it is uncertain whether they represent bonafide cases due to the lack of molecular confirmation. 42, 43 From a practical standpoint, tumors with rhabdoid morphology in adults are almost invariably poorly differentiated to undifferentiated carcinomas.
The prognosis of urothelial carcinoma with rhabdoid morphology is uniformly is poor and characterized by an aggressive clinical course with an average survival of 5 months.
24,35,44

Lipoid Cell Variant
The most recent WHO (2004) classification recognizes that rare urothelial carcinomas may be composed of tumor cells resembling lipoblasts. 1, 45 Although they were referred to a ''lipid-cell'' carcinoma, the term ''lipoid cell'' may be more appropriate as the exact nature of the cytoplasmic content of these cells has not been studied conclusively in human subjects. The cytoplasm of the tumor cells is reported to stain with Alcian Blue and periodic acid-Schiff stains. 31 Borzacchiello et al 46 have studied a case of a lipid-rich variant of urothelial carcinoma in a cow and demonstrated intracytoplasmic staining of lipid with Sudan black and Oil Red O stains.
Lipoid cell variant is defined as a urothelial carcinoma having optically clear, empty, multivacuolated cytoplasm resembling lipoblasts (Fig. 8) . The nuclei are enlarged and often indented. The lipoid cell population generally comprises between 10% and 50% of the overall tumor and is invariably within and associated with highgrade conventional urothelial carcinoma. Mitoses are usually sparse in the lipoid cells.
The first example of this variant was described by Soylu et al, 30 who described an aggressive urothelial neoplasm showing both plasmacytoid and lipoid tumor cells. Leroy et al 31 have since reported the largest series to date of 5 cases of this variant in 2007. In their series, the authors found that all 5 cases stained strongly with CK7 and EMA whereas 4 of the 5 cases stained for CK20, thus confirming their epithelial, and supporting their urothelial nature. This particular variant seems to be associated with the presence of other variants of urothelial carcinoma, with 2 cases associated with the plasmacytoid variant 30, 31 and another case associated with the micropapillary variant of urothelial carcinoma. 31 Patients seem to follow an aggressive clinical course with most patients dying as a result of local disease progression or widespread metastasis. 31, 47 It is not clear whether the poor prognosis is due to the lipoid cells (unlikely in our opinion) or merely a reflection of the association of this histology with high stage urothelial carcinoma.
As this finding is usually focal or patchily conspicuous within a tumor, the diagnosis is usually straightforward, however, distinction from a signet ring cell adenocarcinoma component of the bladder or a liposarcoma (heterologous element of sarcomatoid carcinoma) involving the urinary bladder may be a consideration.
UROTHELIAL CARCINOMA WITH TROPHOBLASTIC DIFFERENTIATION
Urothelial carcinomas with trophoblastic differentiation span a spectrum: (1) conventional urothelial carcinoma with b-hCG immunoreactivity, (2) urothelial carcinoma with scattered syncytiotrophoblasts, and (3) urothelial carcinoma with choriocarcinomatous component; pure choriocarcinoma of the urinary tract has been reported. [48] [49] [50] For the diagnosis of urothelial carcinoma with trophoblastic differentiation, a component of conventional high-grade urothelial carcinoma must be identified before the diagnosis is entertained. Currently, there is no clear indication for routinely performing b-hCG immunostaining for diagnostic or prognostic purposes. In cases where the staining is performed, b-hCG-positive areas may be intermixed with b-hCG-negative areas that look morphologically identical. Syncytiotrophoblasts may be seen in up to 12% of urothelial carcinomas (Figs. 9A,  B) . 51 Although primary choriocarcinomas of the bladder have been reported to occur, given their rarity, the diagnosis should be made with extreme caution and every attempt must be made to rule out a metastatic tumor before the diagnosis is rendered (Figs. 9C, D) . 52, 53 There has been a single case report in a 19-year-old male, documenting a pure choriocarcinoma of the bladder that was confirmed by the presence of an isochromosome 12p, which is a specific cytogenetic abnormality found in germ cell tumors. 54 Despite the occurrence of isolated cases, it is worthwhile to rule out the possibility of a regressed testicular primary in men, a phenomenon that is well documented, as a testicular scar may be the only sign of a testicular primary in these patients. In addition to conventional urothelial carcinoma, a trophoblastic component has been described in association with certain variants of urothelial carcinoma, including sarcomatoid urothelial carcinoma, plasmacytoid urothelial carcinoma, and micropapillary urothelial carcinoma. 34, 55, 56 Immunoreactivity for trophoblastic hormones is found in approximately 36% of all urothelial carcinomas. 57 The frequent expression of trophoblastic markers in urothelial carcinomas had led to much speculation about the origin of these tumors. Some believe that trophoblastic differentiation arises from embryologic rests, whereas others believe that it arises from urothelium, 58 which has the ability for pluripotential differentiation. There has been recent data suggesting that the expression of b-hCG by urothelial carcinoma correlates with a higher tumor stage and grade and that identification of this hormone by immunohistochemistry may help identify urothelial carcinomas that behave in a more aggressive fashion and may be resistant to treatment. 59, 60 Additionally, elevated serum b-hCG levels may be associated with a decreased response to radiation therapy. 61 Recently, type II b-hCG genes have been found to be up-regulated in nontrophoblastic cancer. bhCG type II gene expression has been found to be expressed in higher levels in urothelial cancer when compared with normal urothelium, indicating that this may be used as a potential biomarker to diagnose bladder cancer. 59, 62 Owing to the potential prognostic and predictive significance of these findings, the presence of trophoblastic differentiation if noted, must always be reported and quantified by the pathologist.
UNDIFFERENTIATED CARCINOMA Small Cell Carcinoma
Small cell carcinoma is listed in the category of neuroendocrine carcinoma of the urinary bladder in the WHO classification. Approximately 400 cases including several recent large series have been reported in the literature. The mean age of presentation is 66 years and there is a striking male predisposition (M:F ratio >3:1). 63, 64 More than 90% of patients present with hematuria; rare cases present with paraneoplastic syndromes including hypercalcemia, Cushing syndrome, and sensory neuropathy. 65 Histologically, these tumors are indistinguishable from small cell carcinomas of the lung except that in approximately 40% to 50% of cases, there is an associated component of urothelial carcinoma, including urothelial carcinoma in situ, squamous carcinoma, adenocarcinoma, or rarely sarcomatoid carcinoma associated with the small cell component. The tumor is composed of sheets and occasionally nests of tumor cells with scant cytoplasm and a high nuclear:cytoplasmic (N:C) ratio (Fig. 10A, plate II) . The chromatin is finely stippled and nucleoli are inconspicuous. Geographic areas of necrosis, a high mitotic rate and areas of crush artifact are also frequently noted, in keeping with the high proliferation rate of these neoplasms. These tumors express neuroendocrine markers including chromogranin and synaptophysin. CK7 is expressed in approximately 60% of cases whereas CK20 is frequently negative, which is in keeping with the immunohistochemical profile reported for extrapulmonary small cell carcinomas. [66] [67] [68] TTF-1 is expressed in almost 40% of small cell carcinomas of the bladder and its mere positivity does not necessarily suggest a metastasis from a pulmonary primary. 64 Additionally, small cell carcinomas of the urinary bladder overexpress c-kit and epidermal growth factor receptor protein in 27% of cases. 69, 70 Although at this time, the expression of these proteins has no known association with any clinicopathologic variables, their detection may have predictive value as they may serve as useful therapeutic targets in the future. p53 protein is expressed in approximately 54% of cases of small cell carcinoma of the bladder. The expression of this protein has no apparent correlation with clinicopathologic variables in small cell carcinoma of the bladder. 66 Comparative genomic hybridization studies show frequent genomic alterations including deletions of 10q, 4q, 5q, and 13q and gain of 8p, 5p, 6p, and 13q. 67 In a recent paper by Cheng et al, 68 molecular genetic evidence has shown a nearly identical pattern of allelic loss in the small cell carcinoma component and the adjacent conventional urothelial carcinoma, with an overall frequency of allelic loss of 90%. This data suggest a common clonal origin for small cell carcinoma and concurrent urothelial carcinoma.
The differential diagnosis includes lymphoma, crushed poorly differentiated urothelial carcinoma, or a metastatic small cell carcinoma from another primary site. The significant morphologic overlap in the immunohistochemical profile of pulmonary and extrapulmonary small cell carcinomas makes the distinction between these 2 entities virtually impossible on the basis of histology alone. In cases where both pulmonary and bladder neoplasms are present, a bladder primary should be favored if there are multiple pulmonary lesions and there is absence of widespread disease elsewhere. In patients with multiple visceral organ involvement including the lung and bladder, it may be difficult to categorically assign a primary site. Close attention should be paid to the overlying epithelial component to identify any urothelial carcinoma component, as this may aid in establishing the urothelial nature of the primary. The possibility of an extension from a prostatic small cell carcinoma extending to the bladder must also be entertained and examination of multiple sections to rule out the presence of a conventional prostatic adenocarcinoma component must be carried out. Another significant diagnostic pitfall is alveolar rhabdomyosarcoma, which may rarely involve the bladder in adult patients. These tumors may occur either in a pure form or as a component of heterologous differentiation in a sarcomatoid carcinoma and may have significant overlap with small cell carcinoma as the typical ''alveolar'' morphology may not be appreciated and the tumor may present with an almost exclusive primitive round cell appearance. Alveolar rhabdomyosarcomas are positive for desmin, myogenin, and Myo D1 and negative for keratin. The diagnostic overlap is compounded by synaptophysin immunoreactivity (hitherto unexplained) in alveolar rhabdomyosarcomas. 69 Most of the patients with small cell carcinoma of the bladder present with muscle invasive disease and approximately 67% patients develop systemic metastases during the disease course. Metastatic sites include lymph nodes, liver, bone, lung, and brain. Treatment strategies include administration of primary chemotherapy when there is any discernable small cell component in the tumor, followed by surgical treatment for locoregional control. 22 Of note is the observation that there is no significant survival difference when comparing patients who have focal small cell histology with patients who have histologically pure small cell carcinomas, thus suggesting that tumors with mixed histologic patterns are best classified as small cell carcinoma. 64 Although the prognosis of small cell carcinoma of the bladder remains poor, its prognosis may be better than its pulmonary counterpart, with reported survival rates ranging from 8% to 40%. 70, 76, 77 Large Cell Neuroendocrine Carcinoma
The range of neuroendocrine tumors in the bladder includes carcinoid tumor, small cell carcinoma, and large cell neuroendocrine carcinoma. There have been less than 10 reported cases of large cell neuroendocrine carcinoma of the bladder. Carcinomas with both pure and mixed histologies that occur in conjunction with other variants of urothelial carcinoma including lymphoepithelioma-like carcinoma, small cell carcinoma, and adenocarcinoma have been reported. 76, [78] [79] [80] The criteria used to define the entity of large cell neuroendocrine carcinoma in the urinary bladder are similar to those used to classify its pulmonary counterpart: (a) neuroendocrine appearance by light microscopy; (b) large polygonal cells with a low N:C ratio; coarse chromatin and frequent prominent nucleoli (Fig. 10B , plate II); (c) a high mitotic rate >10 mitoses/10 highpower fields accompanied by multiple areas of necrosis; and (d) immunohistochemical or ultrastructural evidence of neuroendocrine differentiation. 71 The differential diagnosis includes metastatic neuroendocrine carcinoma from other sites including the prostate. Meticulous exclusion of another primary by clinical and imaging studies is important. The presence of a conventional urothelial carcinoma component would indicate a primary in the bladder. As in the lung, large cell neuroendocrine carcinoma may be underreported in the bladder, if the diagnosis is not initially considered and the appropriate diagnostic work up is not performed. 72 The outcome of large cell neuroendocrine carcinoma seems to be similar to small cell carcinoma with most reported cases following an aggressive clinical course. [73] [74] [75] Owing to the small number of reported cases, it is difficult to draw any conclusions with regards to optimal treatment strategy for these tumors. However, a recent study on neuroendocrine tumors of the bladder suggests that adjuvant chemotherapy may offer a survival advantage to patients when compared with cystectomy alone. 76 
Lymphoepithelioma-like Carcinoma
First reported in 1991, there have been less than a 100 cases to date in the literature. 77 Tumors bear a striking resemblance to undifferentiated carcinomas of the nasopharynx, from where they derive the name ''lymphoepithelioma.'' Clinically, patients often present with hematuria. 78 The tumors are usually solitary and may be relatively small in size. Histologically, the neoplastic cells are large and arranged in syncytia. The individual tumor cells have large, pleomorphic vesicular nuclei, prominent nucleoli, and numerous mitoses; the cytoplasmic borders are commonly indistinct (Fig. 11) . The background consists of a mixture of polyclonal B and T lymphocytes, histiocytes, eosinophils, and plasma cells. The inflammatory infiltrate may be so dense as to obscure the epithelial component of the tumor, thus raising the diagnostic concern for a lymphoma. The Epstein-Barr virus (EBV) has been associated with lymphoepithelioma-like carcinomas in certain anatomic sites; however, there is no association with tumors of the urinary bladder. 79 In a study of 30 cases of lymphoepithelioma-like carcinoma of the urinary bladder, Tamas et al 80 found no labeling in any of their cases with EBV-encoded RNA. Their findings essentially confirmed the findings of Gulley et al 79 who had found all cases of lymphoepithelioma-like carcinomas in their series to be uniformly negative for EBV. The expression of p53 protein by lymphoepithelioma-like carcinomas at other sites, has been shown to be strongly associated with the presence of EBV; and there is a strong correlation with the EBV-encoded RNA status and the presence of the p53 protein at these sites. A single study has documented the widespread and intense expression of p53 protein in lymphoepithelioma-like carcinomas of the urinary bladder despite the absence of the EBV protein in these tumors. 81 This finding may be explained due to alteration of the p53 pathway in up to 75% of urothelial carcinomas, with an increasing incidence with higher grade tumors. 82 The main differential diagnosis is that of a primary or secondary lymphoma involving the urinary bladder. The diagnosis of malignant lymphoma can usually be resolved by immunohistochemical stains for lymphoid The overall quantity of lymphoepithelioma-like areas within a tumor appears to have a bearing on the prognosis. These tumors can be categorized based on the quantity of the lymphoepithelioma-like component into pure, predominant (>50%), and focal (<50%). When present in a pure or predominant form, lymphoepithelioma-like carcinoma seems to have a favorable outcome which may be related to the host response that manifests as a dense inflammatory infiltrate or due to these patients presenting early for treatment as a consequence of symptoms related to the inflammatory infiltrate. 78, 83, 84 When the lymphoepithelioma-like component is present as a focal component of an otherwise conventional high-grade urothelial carcinoma, the outcome is no different than that of a conventional urothelial carcinoma of similar stage. In the series by Tamas et al, 80 for cases treated with cystectomy, the overall 5-year recurrence-free risk was 59% (62% and 57%, for pure and mixed lymphoepithelioma-like carcinoma, respectively). Owing to the relative rarity of this entity, the optimum treatment strategy for these cases has yet to be developed but there have been encouraging results with cisplatin-based chemotherapy. 85 The response to chemotherapeutic agents, coupled with the better prognosis when compared with conventional urothelial carcinoma of similar stage has led authors to suggest that radical cystectomy may be avoidable in pure forms of lymphoepithelioma-like carcinoma. 86 
Osteoclast-rich Undifferentiated Carcinoma
Kitazawa et al 87 reported the first case in the bladder of a giant cell containing lesion resembling giant cell tumor of the bone. Since then, less than 25 cases of this entity have been reported in the literature. These tumors have a strong male preponderance with most patients being in their 7th decade of life. 88 Histologically, these tumors are composed of mononuclear cells, osteoclast-like giant cells, and recognizable usual urothelial neoplasia (carcinoma in situ, papillary, or invasive carcinoma) in varying proportions. Some areas may be entirely composed of histology similar to giant cell tumor of bone, whereas other areas may show single cells or aggregates of mononuclear cells with a spectrum of atypia with marked pleomorphism, but distinct from the nuclei of the giant cells (Fig. 12B) . 88 The mononuclear component in these tumors stain with antibodies against CD68, pancytokeratin, EMA, CAM 5.2, and CK7; and rarely for S-100 protein, actin, desmin, and p53. The osteoclastic component stains strongly with antibodies against CD51 and CD54, as well as with acid phosphatase, all of which are known be markers of osteoclastic differentiation. 88, 89 There have been cases associated with pseudosarcomatous stromal reaction and heterologous differentiation. 90 Although these tumors have several histologic features of their skeletal counterparts including areas with blood-filled cysts mimicking aneurysmal bone cyst (Fig. 12C) , the association of a conventional urothelial carcinoma component coupled with the matched p53 and epithelial marker positivity in the mononuclear cells and the adjacent urothelial carcinoma suggests that these tumors should be considered as variants of urothelial carcinoma. 88, 91, 92 The differential diagnosis includes other giant cell containing lesions of the urinary bladder including giant cell carcinoma, sarcomatoid urothelial carcinoma with anaplastic giant cells, high-grade urothelial carcinoma with syncytiotrophoblasts and/or choriocarcinomatous elements, urothelial carcinoma with osteoclast-like stromal response, and urothelial carcinoma with treatmentassociated giant cells (post-BCG or posttransurethral resection). It should be noted that conventional urothelial carcinoma with focal osteoclast-like giant cells in the stroma should not be misclassified as osteoclast-rich undifferentiated carcinomas of the bladder.
The prognosis for these tumors when correctly diagnosed seems to be poor and most patients follow an aggressive clinical course. In the series of 6 cases reported by Baydar et al, 88 4 of 5 patients in whom follow-up was available died of disease. Additionally, a large majority of patients published in case reports, in whom adequate follow-up is available, have also been reported to have metastatic disease or death due to disease.
SUMMARY
In summary, we have updated information on selected histologic variants of urothelial carcinoma including those that have been recently described. The accurate recognition of these ''variant'' morphologies is of paramount importance due to the diagnostic dilemma that they may present, as well as prognostic and therapeutic implications these diagnoses may have.
